Jordan Knepper

Outcomes after late explantation of aortic endografts depend on indication for explantation.

BACKGROUND With the growing prevalence of endovascular repair for abdominal aortic aneurysm (AAA), the number of patients requiring graft explantation is increasing. Therefore, knowledge related to outcomes after explantation may lead to improvement in surgical options. In this study we compare our experience with explantation of aortic endografts, based on indication. METHODS The medical records of all aortic procedures performed at our center were queried during the period from 2002 to 2012. Relevant data from patients needing explantation of aortic endografts were analyzed using Fishers exact test, t-test, and Kaplan-Meier analysis. RESULTS Thirty-nine patients underwent aortic endograft explantation (64.1% men). Mean age was 71.9 years with a mean aneurysm size of 6.8 cm (range 3.5-10.7 cm). Hypertension (97.4%), hyperlipidemia (76.9%), and history of smoking (82%) were the most prevalent risk factors. Mean time to explant was 41.7 months (range 2.2-118.4 months). The primary explant indication was endoleak in 27 (69.2%) and infection in 12 (30.8%) patients. The endoleak group consisted of 13 type I, 8 type II, 1 type III, 4 endotension, 1 rupture, and 4 patients with multiple endoleaks. Seven patients were symptomatic, whereas 2 had ruptured aneurysms. Half of the patients in the infection group required supraceliac clamping for explantation. Operative blood loss (P = 0.08) and need for transfusion (P = 0.005) were significantly higher in the infection group. Thirty-day morbidity was 51.8% for the endoleak group and 83% for the infection group (P = 0.08). There were only 2 deaths in the cohort within 30 days, both in the infection group. Twenty-seven patients were alive at a mean follow-up of 1.9 years (range 0.1-8.4 years). CONCLUSIONS Endograft explantation is a challenging operation with high morbidity and mortality. Furthermore, patients with an infectious etiology have significantly worse outcomes than those requiring explantation for endoleaks.

A Review of Clinical Trials and Registries in Descending Thoracic Aortic Aneurysms

Aortic disease is a significant pathology, as it represents the 12(th) leading cause of overall death. Aneurysms of the descending thoracic aorta pose a small but significant part of this pathology. Traditional open descending thoracic aortic aneurysm (TAA) repair continues to be performed despite relatively high morbidity and mortality rates. As endovascular therapy to treat vascular disease has evolved, a paradigm shift has occurred such that likely most isolated TAAs are now repaired with an endovascular approach. Multiple, prospective trials have been performed comparing open and endovascular TAA repair with three company sponsored trials documenting clinical equipoise. In these studies, endovascular thoracic aortic aneurysm repair (ETAR) was mostly compared with historic controls or open repair from centers of excellence. While the trials all indicate that 30-day peri-operative morbidity and mortality is lower in the ETAR group, these trials were not designed to determine which patient is best served by an open versus an endovascular approach. In addition, long-term follow-up data is limited. Registry data of patients undergoing ETAR seems to mirror that of the aforementioned clinical trials and indicates acceptable morbidity and mortality profiles when compared to published open TAA repair results. Future prospective studies focused on patient selection likely will never be performed, as most believe the benefits of ETAR outweigh the lack of long term follow up data. This review will focus on repair of TAA, specifically clinical trial and registry data comparing open and endovascular repair.

Evolution in the Management of Aberrant Subclavian Arteries and Related Kommerell Diverticulum

BACKGROUND Various options have been described to treat aberrant subclavian arteries and associated Kommerell diverticulum. We describe our experience with the management of this entity over a 15-year period. METHODS Twenty-two patients underwent repair of aberrant subclavian arteries and associated Kommerell diverticulum. Indications for intervention included a large Kommerell diverticulum (n = 18), dysphagia lusoria (n = 12), rupture (n = 4), type B aortic dissection (n = 4), thoracic aortic aneurysm (n = 2), and coarctation (n = 1). Patients were treated with either open surgery (n = 9) or an endovascular approach (n = 13). For the open surgical patients, hypothermic circulatory arrest (n = 7) or left heart bypass (n = 2) was used. For those patients undergoing an endovascular approach (n = 13), carotid to subclavian arterial bypasses were performed preoperatively in 11 patients and intraoperatively in 2 patients. Bilateral revascularization was more frequently performed with endovascular repair compared with open surgery (69% vs 22%, p = 0.01). RESULTS Early outcomes included in-hospital mortality (n = 1), stroke (n = 1), and permanent spinal cord ischemia (n = 1) after endovascular approaches, and renal failure requiring dialysis (n = 1) and need for tracheostomy (n = 1) after open repair. The frequency of endovascular repair increased after the commercialization of thoracic endovascular aortic repair in 2005 from 33% to 63%. Four patients developed type I (n = 1) or type II (n = 3) endoleaks, of which 1 required reintervention. Median hospital stay was 7 days (interquartile range 4 to 17). Five-year survival was 81.8%. No late aortic ruptures occurred and 3 patients required late reintervention; 1 after an open and 2 after an endovascular approach. Dysphagia lusoria was relieved in all patients except for 1 in the open repair and 1 in the endovascular group. CONCLUSIONS Aberrant subclavian arteries and associated Kommerell diverticulum can be treated with acceptable rates of mortality and morbidity. The evolution toward an endovascular approach did not appear to affect late outcomes, suggesting that the choice of treatment should be based on patient-specific anatomy and associated comorbidities.

Open Mesenteric Interventions Are Equally Safe as Endovascular Interventions and Offer Better Midterm Patency for Chronic Mesenteric Ischemia

BACKGROUND Endovascular (EV) techniques are being advocated as the preferred method for mesenteric interventions because of their safety profile. However, midterm and long-term results are thought to be inferior to open interventions. We sought to compare our institutional experience with treatment of acute and chronic mesenteric ischemia (AMI and CMI, respectively) using EV and open techniques. METHODS The medical records of open and EV mesenteric procedures performed at a single center were queried from 2002 to 2012. Demographic, perioperative, and follow-up data were extracted and analyzed. RESULTS Thirty-eight patients underwent EV mesenteric interventions, whereas 77 patients underwent open revascularization. The demographic and perioperative characteristics for patients were similar. Most EV procedures (89.2%) comprised stenting, whereas open procedures included 25 (32.1%) antegrade bypasses, 38 (48.7%) retrograde bypasses, 8 (10.3%) thromboembolectomies, and 7 (9%) transaortic endarterectomies. Postoperative complications, overall 30-day morbidity and mortality were not significantly different in the open and EV groups for AMI or CMI. Thirty-day mortality in AMI (n = 34) was 38.2% (EV: 45.5% vs. open: 34.8%; P = nonsignificant). There was no mortality in either group for CMI patients. Mean follow-up was much longer for the open procedures (34.9 vs. 12.7 months, P = 0.004). Primary and secondary patency rates were better for open revascularization for CMI patients. CONCLUSIONS Open revascularizations are equally safe as EV interventions for AMI and CMI. Patency of open revascularization for CMI is better than EV procedures at midterm follow-up.

Surgical treatment of Kommerell's diverticulum and other saccular arch aneurysms

BACKGROUND Saccular aneurysms of the aortic arch are rare, and their surgical repair is challenging with potentially significant morbidity and mortality. METHODS We examined our experience over a 3-year period with nine consecutive patients that include nine hybrid repairs with initial extra-anatomic carotid and/or subclavian bypass and subsequent endovascular exclusion of the saccular arch aneurysm. RESULTS Three patients presented with dysphagia from aberrant right subclavian arteries with aneurysm at the origin of the artery, two had asymptomatic aneurysms at the origin of the left subclavian, and four patients had isolated saccular aneurysms of the arch, three of whom presented with thoracic pain. A total of 16 extra-anatomic bypasses were done in the nine patients. Ten endografts and one nitinol plug were used for exclusion in the nine hybrid cases. There were no perioperative deaths, no strokes, or myocardial infarction events. During follow-up, two patients (22%) were found to have type II endoleaks, but no reinterventions were required. Symptoms resolved in six patients, whereas persistent dysphagia and pain occurred in one. CONCLUSIONS Repair of saccular aneurysms of the aortic arch by hybrid approach can be done with minimal morbidity and mortality and a reasonable rate of symptom resolution.

Novel anticoagulants: A discussion of clinical use in the treatment and prevention of venous thromboembolism

Traditional therapeutic oral anticoagulation strategies often require invasive dosing or monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed onset requires frequent dose monitoring, and they have a small margin between therapeutic dose and bleeding complications. Novel oral anticoagulants, such as dabigatran, rivaroxaban and apixaban, are being developed to prevent those VKAs drawbacks. Besides oral bioavailability, those compounds are designed to require minimal to no monitoring and have a favourable safety profile. This review reports efficacy and safety data of these compounds throughout clinical development, as well as new approaches for oral pharmacological management of venous thromboembolism.

Surgical Management of Recurrent Infectious Perivisceral Aortitis With Expanding Aortic Stump Pseudoaneurysm

Here we present a case of recurrent aortic graft infection (AGI) in a 77yearold male resulting in progressive perivisceral aortitis and aortic stump pseudoaneurysm one year following graft explantation and creation of an infrarenal aortic stump for AGI. Recurrent AGI is a common, yet diverse, disease process that carries substantial morbidity and mortality. Following initial medical management with broadspectrum antibiotics, the patient was treated surgically with visceral debranching off the thoracic aorta and creation of a descending thoracic aortic stump. In this case, rifampinbonded grafts were utilized and the diaphragm was used for aortic reinforcement. The extent of the phlegmon prevented extensive source control, requiring longterm parenteral broadspectrum antibiotics including antifungal coverage against Candida albicans. The incidence of AGI is relatively low. Reinfection after surgical management for AGI is significantly more common and associated with worse clinical outcomes. The complex presentation and surgical repair presented in this case highlight the importance of individualized surgical and medical management for recurrent AG